See more : Ledlink Optics, Inc. (5230.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Ardmore Shipping Corporation (ASC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ardmore Shipping Corporation, a leading company in the Marine Shipping industry within the Industrials sector.
You may be interested
- Crixus BH3 Acquisition Company (BHACU) Income Statement Analysis – Financial Results
- Vadilal Enterprises Limited (VADILENT.BO) Income Statement Analysis – Financial Results
- Nok Airlines Public Company Limited (NOKFF) Income Statement Analysis – Financial Results
- Daqin Railway Co., Ltd. (601006.SS) Income Statement Analysis – Financial Results
- Junhe Pumps Holding Co., Ltd (603617.SS) Income Statement Analysis – Financial Results
Ardmore Shipping Corporation (ASC)
About Ardmore Shipping Corporation
Ardmore Shipping Corporation engages in the seaborne transportation of petroleum products and chemicals worldwide. As of February 15, 2022, the company operated a fleet of 25 double-hulled product and chemical tankers. It serves oil majors, oil companies, oil and chemical traders, chemical companies, and pooling service providers. The company was founded in 2010 and is based in Pembroke, Bermuda.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 395.98M | 445.74M | 192.48M | 220.06M | 230.04M | 210.18M | 195.94M | 164.40M | 157.88M | 67.33M | 35.87M | 25.17M | 22.38M |
| Cost of Revenue | 242.61M | 250.21M | 188.04M | 121.01M | 128.38M | 133.28M | 107.01M | 67.21M | 54.29M | 21.86M | 10.91M | 8.68M | 7.47M |
| Gross Profit | 153.37M | 195.53M | 4.44M | 99.05M | 101.66M | 76.90M | 88.93M | 97.19M | 103.59M | 45.47M | 24.96M | 16.49M | 14.90M |
| Gross Profit Ratio | 38.73% | 43.87% | 2.31% | 45.01% | 44.19% | 36.59% | 45.39% | 59.12% | 65.61% | 67.53% | 69.58% | 65.50% | 66.59% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.57M | 24.11M | 19.20M | 17.90M | 18.15M | 15.86M | 14.60M | 14.08M | 10.75M | 8.18M | 5.67M | 2.98M | 2.60M |
| Selling & Marketing | 4.68M | 4.17M | 3.13M | 2.78M | 3.19M | 3.23M | 2.62M | 2.02M | 329.75K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.24M | 24.11M | 19.20M | 17.90M | 18.15M | 15.86M | 14.60M | 14.08M | 10.75M | 8.18M | 5.67M | 2.98M | 2.60M |
| Other Expenses | 0.00 | 11.97M | 5.17M | 62.55M | 67.35M | -3.64M | -2.92M | -2.72M | -2.12M | -2.03M | -1.42M | -441.49K | 0.00 |
| Operating Expenses | 25.24M | 36.08M | 24.37M | 80.45M | 85.50M | 86.52M | 80.41M | 73.19M | 59.29M | 39.66M | 25.31M | 18.01M | 14.79M |
| Cost & Expenses | 240.03M | 286.29M | 212.41M | 201.46M | 213.87M | 219.80M | 187.42M | 140.40M | 113.58M | 61.52M | 36.22M | 26.70M | 22.26M |
| Interest Income | 1.82M | 471.00K | 55.09K | 281.62K | 952.19K | 606.67K | 436.20K | 164.63K | 15.57K | 16.44K | 6.06K | 4.71K | 3.61K |
| Interest Expense | 11.41M | 15.54M | 16.77M | 18.17M | 26.76M | 27.41M | 21.38M | 17.75M | 12.28M | 4.12M | 3.46M | 2.71M | 2.79M |
| Depreciation & Amortization | 27.82M | 33.44M | 36.87M | 38.39M | 37.13M | 38.78M | 37.20M | 32.81M | 24.16M | 14.85M | 8.39M | 6.20M | 5.34M |
| EBITDA | 157.85M | 187.83M | 11.83M | 50.63M | 40.55M | 21.14M | 46.14M | 54.37M | 68.46M | 20.66M | 8.04M | 4.67M | 5.46M |
| EBITDA Ratio | 39.86% | 42.45% | 6.15% | 23.21% | 21.49% | 12.43% | 22.06% | 33.00% | 43.37% | 30.72% | 22.43% | 17.55% | 23.11% |
| Operating Income | 155.95M | 159.93M | -19.87M | 18.88M | 17.12M | -9.62M | 8.51M | 24.00M | 44.30M | 5.81M | -350.93K | -1.53M | 115.02K |
| Operating Income Ratio | 39.38% | 35.88% | -10.32% | 8.58% | 7.44% | -4.58% | 4.34% | 14.60% | 28.06% | 8.63% | -0.98% | -6.06% | 0.51% |
| Total Other Income/Expenses | -37.67M | -49.87M | -16.49M | -24.73M | -43.77M | -33.16M | -20.94M | -20.19M | -12.27M | -4.10M | -3.46M | -2.96M | -3.08M |
| Income Before Tax | 118.28M | 138.86M | -36.37M | -5.85M | -22.80M | -42.78M | -12.43M | 3.81M | 32.03M | 1.71M | -3.81M | -4.49M | -2.96M |
| Income Before Tax Ratio | 29.87% | 31.15% | -18.89% | -2.66% | -9.91% | -20.35% | -6.34% | 2.32% | 20.29% | 2.54% | -10.62% | -17.83% | -13.24% |
| Income Tax Expense | 435.00K | 207.00K | 149.59K | 199.45K | 58.77K | 162.92K | 59.57K | 60.43K | 79.86K | 46.75K | 33.73K | 51.24K | 13.43K |
| Net Income | 116.81M | 138.45M | -36.52M | -6.05M | -22.86M | -42.94M | -12.49M | 3.75M | 31.95M | 1.66M | -3.84M | -4.54M | -2.98M |
| Net Income Ratio | 29.50% | 31.06% | -18.97% | -2.75% | -9.94% | -20.43% | -6.37% | 2.28% | 20.24% | 2.47% | -10.71% | -18.03% | -13.30% |
| EPS | 2.76 | 3.63 | -1.08 | -0.18 | -0.69 | -1.31 | -0.37 | 0.12 | 1.23 | 0.07 | -0.31 | -0.56 | -0.37 |
| EPS Diluted | 2.71 | 3.52 | -1.08 | -0.18 | -0.69 | -1.31 | -0.37 | 0.12 | 1.23 | 0.07 | -0.31 | -0.56 | -0.37 |
| Weighted Avg Shares Out | 41.13M | 37.24M | 33.88M | 33.24M | 33.10M | 32.78M | 33.44M | 30.14M | 26.06M | 24.55M | 12.24M | 8.05M | 8.05M |
| Weighted Avg Shares Out (Dil) | 41.82M | 38.36M | 33.88M | 33.24M | 33.10M | 32.84M | 33.44M | 30.14M | 26.06M | 24.55M | 12.24M | 8.05M | 8.05M |
Ardmore Shipping Corporation (ASC) Is a Trending Stock: Facts to Know Before Betting on It
Ardmore Shipping (ASC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wall Street Analysts Think Ardmore Shipping (ASC) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Investors Heavily Search Ardmore Shipping Corporation (ASC): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Ardmore Shipping (ASC). This makes it worthwhile to examine what the stock has in store.
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100.
Ardmore Shipping: Appealing Again At A Massive Discount And Attractive Yield; Rating Upgrade
The third quarter results were not that bad. Compared to 3Q23, Ardmore realized higher revenue, EBITDA, and EPS. According to the company's estimates, an additional $10,000 per day equals an annual increase of about $2.25 in EPS increase and nearly...
Ardmore Shipping: Recent Sell-Off Has Created A Golden Buying Opportunity
Ardmore Shipping's strategic advantage lies in its eco-friendly fleet and operational flexibility, enabling it to capitalize on shifting market dynamics between chemical and petroleum products. Q3 results showed double-digit growth in revenue and EPS, along with improved TCE rates and...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China , Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of...
Ardmore Shipping Corporation (ASC) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Ardmore Shipping (ASC). This makes it worthwhile to examine what the stock has in store.
Ardmore Shipping (ASC) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do...
Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity
Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection , demonstrated a half-life of 21 days , supporting once-monthly administration in patients...
Source: https://incomestatements.info
Category: Stock Reports